Evidence for GLP-1 receptor agonists: A meta-analysis by Rivera et al. [77] (13 studies, n=83258) reported that GLP-1 receptor agonists reduced MACE (OR 0.86, 95% CI (0.80 to 0.94), p < 0.01), all-cause mortality (OR 0.87, 95% CI (0.82 to 0.93), p < 0.001), CV mortality (OR 0.87, 95% CI (0.81 to 0.94), p < 0.001), and stroke (fatal and non-fatal). This evidence concerns the gene GLP1R and stroke disorder.